MTOR and hepatocellular carcinoma: Insulin resistance activates IGF-1 and IRS-1 signaling—particularly the PI3K/AKT/mTOR pathway—while metabolic dysregulation and upregulation of LINC01572 further promote HCC through enhanced glycolysis, ROS production, and p53 mutations [42,43].